Zepbound Guide
Zepbound is the brand-name formulation of tirzepatide 2.5–15mg that Eli Lilly launched in late 2023 for long-term weight management. In 2024 its label gained a second use: treating moderate to severe obstructive sleep apnea when an adult also has obesity. It is chemically identical to Mounjaro but approved specifically for obesity treatment, making it eligible for different insurance coverage pathways and savings programs.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
At a Glance
| Generic Name | Tirzepatide |
| Brand Names | Zepbound |
| FDA Status | FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled at BMI ≥30, or ≥27 with a comorbidity) (November 2023), and in adults with obesity, for moderate to severe obstructive sleep apnea (December 2024)[1] |
| Approval Date | November 8, 2023[1] |
How does Zepbound work?
Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects. GLP-1 activation creates feelings of fullness and slows digestion; GIP activation may additionally enhance fat metabolism and energy expenditure. This twin-hormone approach produces more weight loss than any single-pathway agent.[2]
Dosing Schedule
Zepbound uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
What side effects does Zepbound cause?
Common: nausea (31%), diarrhea (23%), vomiting (13%), constipation (12%), abdominal pain (9%), injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), thyroid tumor risk noted in animal models. The suicidal behavior and ideation section was removed from the label in February 2026.[1][2]
Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].
Clinical Trial Results
In the SURMOUNT-1 trial, Zepbound (tirzepatide 15mg) produced an average weight loss of 20.9% over 72 weeks. The lower doses ran 19.5% at 10mg and 15.0% at 5mg, against 3.1% on placebo. Against the 5%-of-body-weight bar, the 15mg dose put 91% of participants over it.[2][3]
Where can you get Zepbound?
Sellers in our register that will dispense tirzepatide, or a compounded version of it, after an online consultation — shipped to your door.
altRX
Best for: compounded semaglutide from $89/month at the same price at every dose
Editorial score · methodology
Editorial score · methodology
RxSpan MD
Best for: knowing which pharmacy fills the vial: it names Belmar Pharmacy
Editorial score · methodology
Luvo Health
Best for: moving between compounded and brand without changing seller
Editorial score · methodology
Editorial score · methodology
Wellorithm
Best for: compounded semaglutide at a flat $247 every 28 days, any dose
Editorial score · methodology
How much does Zepbound cost?
66 sellers in the register publish a price; the lowest starts at $299 a month, checked November 2026. What each one charges to start, cheapest at the top. Compounded tirzepatide from state-licensed 503A pharmacies is legal under federal compounding law when made for an individual patient[4], and the rules loosen further, to include bulk compounding by 503B outsourcing facilities, only while a molecule sits on the FDA Drug Shortage List[5]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[6]. What you actually pay moves with your dose and with whatever promotion happens to be running.
| Provider | Starting Price | Link | |
|---|---|---|---|
| Amazon One Medical | brand | $299/mo | Visit |
| Aspire Health | brand | $299/mo + care fee | Visit |
| Found | brand | $299/mo + membership | Visit |
| GoodRx | brand | $299/mo | Visit |
| Heally | brand | $299/mo | Visit |
| Healthspan | brand | $299/mo + membership | Visit |
| Hims | brand | $299/mo + membership | Visit |
| Imbue Health | brand | $299/mo + membership | Visit |
| Intermountain Health On-Demand Weight Loss | brand | $299/mo + consult fee | Visit |
| Klinic | brand | $299/mo | Visit |
Show all 66 Zepbound sellersShowing all 66 sellers
| Knownwell | brand | $299/mo + visit fee | Visit |
| LillyDirect | brand | $299/mo | Visit |
| médetone | brand | $299/mo + membership | Visit |
| Mochi Health | brand | $299/mo + membership | Visit |
| PreventiveMD | brand | $299/mo | Visit |
| Ro | brand | $299/mo + membership | Visit |
| Sculpt Rx | brand | $299/mo + membership | Visit |
| Sesame Care | brand | $299/mo + care fee | Visit |
| ShedRx | brand | $299/mo + membership | Visit |
| Walgreens Weight Management | brand | $299/mo + visit fee | Visit |
| WeightWatchers Clinic | brand | $299/mo + membership | Visit |
| ZipHealth | brand | $299/mo + fees | Visit |
| Noom | brand | $349/mo | Visit |
| GOAL.MD | brand | $394/mo | Visit |
| Alloy | brand | $398/mo | Visit |
| Phoenix NP | brand | $403/mo | Visit |
| Navio MD | brand | $445/mo | Visit |
| LifeMD | brand | $448/mo | Visit |
| Maximus | brand | $449.99/mo | Visit |
| Immortals | brand | $600/mo, prepaid | Visit |
| WePeptideRx | brand | $699/mo | Visit |
| Pallas Health | brand | $1,069/mo | Visit |
| RxSpan MD | brand | $1,069/mo | Visit |
| Josie | brand | $1,099/mo | Visit |
| Wellorithm | brand | $1,199/mo, prepaid | Visit |
| altRX | brand | $1,249/mo | Visit |
| Wellya | brand | $1,249/mo | Visit |
| RxION Health | brand | $1,259/mo | Visit |
| Elevate Health | brand | $1,289/mo | Visit |
| NoBsRx | brand | $1,299/mo | Visit |
| Astra | brand | $1,300/mo | Visit |
| DudeMeds | brand | $1,350/mo | Visit |
| Oak | brand | $1,350/mo | Visit |
| HeliMeds | brand | $1,396/mo, prepaid | Visit |
| Aquivia Health | brand | $1,399/mo | Visit |
| GobyMeds | brand | $1,399/mo | Visit |
| Luvo Health | brand | $1,399/mo | Visit |
| Peptivo | brand | $1,399/mo | Visit |
| Remmy | brand | $1,399/mo | Visit |
| Tomorrow | brand | $1,399/mo | Visit |
| TrimRx | brand | $1,399/mo | Visit |
| Tryozi | brand | $1,399/mo | Visit |
| Vytora Health | brand | $1,399/mo | Visit |
| XMD Wellness | brand | $1,399/mo | Visit |
| Effecty | brand | $1,400/mo | Visit |
| Elara Women's Wellness | brand | $1,400/mo | Visit |
| SkinnyRx | brand | $1,400/mo | Visit |
| OrderlyMeds | brand | $1,498/mo | Visit |
| BiltRx | brand | $1,499/mo | Visit |
| Corsica Health | brand | $1,499/mo | Visit |
| WellMedRx | brand | $1,599/mo | Visit |
| Good Girl Rx | brand | $1,688/mo | Visit |
| Layla | brand | $1,699/mo | Visit |
| Fridays | brand | $1,828/mo | Visit |
| Nucific | brand | $1,828/mo | Visit |
| NuuVim | brand | $1,892/mo | Visit |
Zepbound Head-to-Head Comparisons
Short verdict pages setting Zepbound against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.
See all drug-vs-drug verdicts.
Pivotal Zepbound Trial Walkthroughs
The trials that produced the Zepbound label, taken endpoint by endpoint, with the figures read off the source.
Zepbound Patient Questions, Answered
Questions people actually asked about Zepbound in named subreddits, each answered from the published trial data.
Zepbound Reference Cards
One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.
Ranked PubMed Studies on Zepbound
The peer-reviewed studies on Zepbound and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.
Related Research on Zepbound
Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.
Frequently Asked Questions
Sources & methodology — as of November 2026
- 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.
- 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Glossary
The words sellers use, defined. Tap any term.
- Tirzepatide · Drugs and brands
- Mounjaro · Drugs and brands
- GLP-1 receptor · Mechanism
- GIP receptor · Mechanism
- Dual agonist · Mechanism
- SURMOUNT-1 · Major trials
- SURMOUNT-OSA · Major trials